drugset
drugset / Trial / NCT06163820

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

NCT06163820 ↗

Phase 1/2 Recruiting 46 enrolled Melanoma and Skin Cancer Trials Limited
NaSingle-groupOpen-labelTreatment

Summary

Single arm phase I/II trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT) in patients with symptomatic melanoma brain metastases (MBM).

Timeline

Start
2025-05-31
Primary completion
2026-01-30
Completion
2026-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Subject Ipilimumab Monoclonal antibody 3 mg/kg —
Subject Nivolumab Monoclonal antibody 480 mg —

Indications

metastatic melanoma